Anti-Heparanase Aptamers as Potential Diagnostic and Therapeutic Agents for Oral Cancer
暂无分享,去创建一个
Dilson Silva | Sotiris Missailidis | Pia Nyberg | T. Salo | J. Risteli | P. Brenchley | C. deAlmeida | S. Missailidis | Tuula Salo | Juha Risteli | S. Salo | P. Nyberg | C. Cortez | Suzanne C. Simmons | Hannaleena Jämsä | Celia M. Cortez | Edward A. McKenzie | Carolina C. Bitu | Sirpa Salo | Sini Nurmenniemi | Carlos E. B. deAlmeida | Paul E. C. Brenchley | Dílson Silva | E. Mckenzie | C. Bitu | S. Nurmenniemi | S. Simmons | Hannaleena Jämsä
[1] Ying-Fon Chang,et al. Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.
[2] A D Ellington,et al. Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.
[3] C. Ferreira,et al. DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers , 2006, Tumor Biology.
[4] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[5] D. Adams,et al. Leucocyte-endothelial interactions and regulation of leucocyte migration , 1994, The Lancet.
[6] I. Vlodavsky,et al. Molecular properties and involvement of heparanase in cancer progression and normal development. , 2001, Biochimie.
[7] R. Goldberg,et al. Heparanase in inflammation and inflammation‐associated cancer , 2013, The FEBS journal.
[8] M. Yanagishita,et al. Expression of heparanase in oral cancer cell lines and oral cancer tissues. , 2001, Oral oncology.
[9] Tibor Hianik,et al. Detection of aptamer-protein interactions using QCM and electrochemical indicator methods. , 2005, Bioorganic & medicinal chemistry letters.
[10] M. Sodeoka,et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. , 2004, Molecular cancer therapeutics.
[11] S. Missailidis,et al. Interactions of aptamers with sera albumins. , 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[12] J. Kiel,et al. Anti-Francisella tularensis DNA aptamers detect tularemia antigen from different subspecies by Aptamer-Linked Immobilized Sorbent Assay , 2006, Laboratory Investigation.
[13] T. Salo,et al. A novel organotypic model mimics the tumor microenvironment. , 2009, The American journal of pathology.
[14] R. Parekh,et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. , 2003, The Biochemical journal.
[15] N. Janjić,et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.
[16] S. Missailidis,et al. A fluorescent spectroscopy and modelling analysis of anti-heparanase aptamers-serum protein interactions. , 2013, Journal of photochemistry and photobiology. B, Biology.
[17] M. Price,et al. Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting. , 2005, Journal of immunological methods.
[18] P. Brenchley,et al. Development of Novel Single-Stranded Nucleic Acid Aptamers against the Pro-Angiogenic and Metastatic Enzyme Heparanase (HPSE1) , 2012, PloS one.
[19] T. Peretz,et al. Site-directed Mutagenesis, Proteolytic Cleavage, and Activation of Human Proheparanase* , 2005, Journal of Biological Chemistry.
[20] Manfred Kansy,et al. Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.
[21] M Yarus,et al. Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.
[22] J. Lakowicz. Principles of fluorescence spectroscopy , 1983 .
[23] O. Pappo,et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis , 1999, Nature Medicine.
[24] J. M. Healy,et al. First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers , 2007, Circulation.
[25] T. Nemoto,et al. Loss of Syndecan‐1 and Increased Expression of Heparanase in Invasive Esophageal Carcinomas , 2001, Japanese journal of cancer research : Gann.
[26] Misako Sato,et al. Heparanase: A Key Enzyme in Invasion and Metastasis of Gastric Carcinoma , 2002, Modern Pathology.
[27] D. Boudreau,et al. Protein Detecting Arrays Based on Cationic Polythiophene–DNA‐Aptamer Complexes , 2006 .
[28] C. Vargeese,et al. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.
[29] G. Jayson,et al. Hypoxia Increases Heparanase-Dependent Tumor Cell Invasion, Which Can Be Inhibited by Antiheparanase Antibodies , 2004, Cancer Research.
[30] T. Salo,et al. Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. , 2012, Oral oncology.
[31] Ying-Fon Chang,et al. Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] R. Hershkoviz,et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH , 1995, The Journal of experimental medicine.
[33] I. Cohen,et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. , 1992, Invasion & metastasis.
[34] G. Nicolson,et al. Human heparanase: a molecular determinant of brain metastasis. , 2001, Advances in enzyme regulation.
[35] Georgia Sotiropoulou,et al. One round of SELEX for the generation of DNA aptamers directed against KLK6 , 2012, Biological chemistry.
[36] Joseph Wang,et al. Label-free bioelectronic detection of aptamer–protein interactions , 2005 .
[37] M. Famulok,et al. Aptamers as tools in molecular biology and immunology. , 1999, Current topics in microbiology and immunology.
[38] H. Friess,et al. The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer , 2001 .
[39] L. McGown,et al. Affinity capture and detection of immunoglobulin E in human serum using an aptamer-modified surface in matrix-assisted laser desorption/ionization mass spectrometry. , 2007, Analytical chemistry.
[40] B. Sullenger,et al. Generation of species cross-reactive aptamers using "toggle" SELEX. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] Yi Lu,et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.
[42] Motowo Nakajima,et al. Expression of three extracellular matrix degradative enzymes in bladder cancer , 2001, International journal of cancer.
[43] I. Vlodavsky,et al. Heparin, heparan sulfate and heparanase in inflammatory reactions , 2009, Thrombosis and Haemostasis.
[44] Benito Casu,et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. , 2007, Current pharmaceutical design.
[45] N. Fiotti,et al. Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors. , 2013, Current drug metabolism.
[46] Michael Musheev,et al. Non-SELEX selection of aptamers. , 2006, Journal of the American Chemical Society.
[47] C. Pisano,et al. Significance of Heparanase in Cancer and Inflammation , 2012, Cancer Microenvironment.
[48] I. Vlodavsky,et al. Substrate Specificity of Heparanases from Human Hepatoma and Platelets* , 1998, The Journal of Biological Chemistry.
[49] R. Baker,et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis , 1999, Nature Medicine.
[50] M. Morra,et al. Assessment of inner filter effect corrections in fluorimetry , 1991 .
[51] P. Gattuso,et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. , 2002, Surgery.
[52] R. Heinrikson,et al. Heterodimer formation is essential for heparanase enzymatic activity. , 2003, Biochemical and biophysical research communications.
[53] T. Eberlein,et al. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] Chao Zeng,et al. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo , 2013, Medical Oncology.
[55] A. Purushothaman,et al. Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes*♦ , 2013, The Journal of Biological Chemistry.
[56] Kemin Wang,et al. Electrochemical detection of thrombin based on aptamer and ferrocenylhexanethiol loaded silica nanocapsules. , 2011, Biosensors & bioelectronics.
[57] L. Kjellén,et al. Regulated Diversity of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.
[58] T. Peretz,et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. , 2002, Seminars in cancer biology.
[59] Z. Fuks,et al. Role of Heparanase in Platelet and Tumor Cell Interactions with the Subendothelial Extracellular Matrix , 1987, Seminars in thrombosis and hemostasis.
[60] T. Peretz,et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. , 2000, The American journal of pathology.
[61] D. Patel,et al. Adaptive recognition by nucleic acid aptamers. , 2000, Science.
[62] R. Palmer,et al. Modification of thiol functionalized aptamers by conjugation of synthetic polymers. , 2010, Bioconjugate chemistry.
[63] L. McGown,et al. Aptamer-enhanced laser desorption/ionization for affinity mass spectrometry. , 2004, Analytical chemistry.
[64] L. Garraway,et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma , 2014, Investigational New Drugs.
[65] H. Friess,et al. Heparanase expression in primary and metastatic pancreatic cancer. , 2001, Cancer research.
[66] F. Zunino,et al. The potential of heparanase as a therapeutic target in cancer. , 2014, Biochemical pharmacology.
[67] J. Bennett,et al. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. , 2005, Bioorganic & medicinal chemistry letters.